中国组织工程研究 ›› 2017, Vol. 21 ›› Issue (21): 3426-3431.doi: 10.3969/j.issn.2095-4344.2017.21.024

• 干细胞综述 stem cell review • 上一篇    下一篇

诱导性多能干细胞在阿尔茨海默病治疗研究中的应用进展

朱世琪1,李 峰2   

  1. 1首都医科大学,北京市 100069;2首都医科大学神经生物学系,北京脑重大疾病研究院,北京神经再生修复研究重点实验室,北京市 100069
  • 修回日期:2017-02-12 出版日期:2017-07-28 发布日期:2017-07-28
  • 通讯作者: 李峰,首都医科大学神经生物学系,北京脑重大疾病研究院,北京神经再生修复研究重点实验室,北京市 100069
  • 作者简介:朱世琪,男,1995年生,河北省邢台市人,汉族,首都医科大学在读硕士,主要从事临床医学研究。
  • 基金资助:

    北京市教育委员会科技发展计划面上项目资助(KM201510025001)

Research advances in induced pluripotent stem cells in Alzheimer’s disease

Zhu Shi-qi1, Li Feng2   

  1. 1Capital Medical University, Beijing 100069, China; 2Department of Neurobiology, Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
  • Revised:2017-02-12 Online:2017-07-28 Published:2017-07-28
  • Contact: Li Feng, Department of Neurobiology, Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
  • About author:Zhu Shi-qi, Studying for master’s degree, Capital Medical University, Beijing 100069, China
  • Supported by:

    the Scientific Research Project of Beijing Educational Commission, No. KM201510025001

摘要:

文章快速阅读:

文题释义:
诱导性多能干细胞:
诱导性多能干细胞技术是日本学者Yamanaka于2006年发现的新型干细胞技术,它是通过一定的诱导因子将成熟体细胞重编程得到具有多分化潜能干细胞的技术,对该干细胞施以相应的分化环境可有目的地获得该成体的相应组织细胞。该技术可应用于疾病模型的建立、药物实验和细胞治疗等方面。
阿尔茨海默病:是一种常见的由多种病因引起的进行性神经退行性疾病,60%-70%的认知功能障碍患者罹患此病,主要表现为脑部神经元纤维蛋白缠结和淀粉样蛋白沉积导致的神经元损伤和进行性认知功能下降。预计2020年全世界将有4 200万人罹患此病。

 

摘要
背景:
诱导性多能干细胞技术是将成熟体细胞重编程得到具有多分化潜能干细胞的技术,可用于疾病模型建立、药物筛选、细胞治疗等方面的研究。
目的:分析诱导性多能干细胞应用于阿尔茨海默病研究的可行性及最新成果,并对现阶段的不足与进一步研究的方向进行总结。
方法:在中国知网与PubMed数据库搜索阿尔茨海默病与诱导性多能干细胞的相关文献。对数据库索引结果进行相关性及重复性筛选,纳入30篇文献进入结果分析。
结果与结论:诱导性多能干细胞为神经退行性疾病的治疗提供了新视野,解决了神经细胞在体获取困难的大难题。利用患者自身细胞诱导形成的诱导性多能干细胞进行治疗更加切实可行,但现阶段该技术仍然面临诸多问题,例如高效稳定的定向分化方法、诱导性多能干细胞的安全性问题、最合适的供体细胞、伦理争议等。

 

 

关键词: 干细胞, 诱导性多能干细胞, 阿尔茨海默病, 药物筛选, 疾病模型, 细胞治疗

Abstract:

BACKGROUND: Induced pluripotent stem cell (iPSC) technique is a newborn technology reprogramming human somatic cells into pluripotent stem cells, which can be used in disease modeling, drug screening and cell therapy.
OBJECTIVE: To analyze the feasibility and advances of iPSC application in Alzheimer’s disease, and conclude the insufficient and future of this technology.
METHODS: CNKI and PubMed were searched for relevant articles concerning Alzheimer’s disease and iPSCs, and the retrieval results were screened by relativity and repeatability. Finally, 30 articles were included in result analysis.
RESULTS AND CONCLUSION: This review concludes the superiority of iPSC technology in the treatment of neurodegenerative diseases and in vivo harvest of nerve cells. The use of inducible pluripotent stem cells differentiated from patient's own cells is more practicable, but there are still many problems to solve at this stage, such as high-efficient and stable directional differentiation, safety of induced pluripotent stem cells, the most appropriate donor cells, and ethical disputes.

 

 

Key words: Multipotent Stem Cells, Alzheimer Disease, Tissue Engineering

中图分类号: